The Effect of Topical Bevacizumab on Corneal Neovascularization

Kim, Sang Woo; Ha, Byung Jin; Kim, Eung Kweon; Tchah, Hungwon; Kim, Tae Im

doi:10.1016/j.ophtha.2008.02.013

Cited by 203 publications

(177 citation statements)

References 24 publications

Supporting

Mentioning

164

Contrasting

Unclassified

Order By: Relevance

“…The eye drops of bevacizumab showed no significant side effects on normal corneal wound healing, its integrity, or density in its nerve fiber [43][44][45][46]. Hosseini and Khalili have shown its usefulness in inhibiting the neovascularisation in herpetic stromal keratitis [47].…”

Section: Discussionmentioning

confidence: 99%

Post-trabeculectomy topical bevacizumab preventing bleb failure: a preliminary study

Bhasker

Saxena

Singh

2012

j ocul biol dis inform

View full text Add to dashboard Cite

This study aims to evaluate the efficacy and safety of post-trabeculectomy topical bevacizumab, in preventing bleb failure. A total of 11 females and 12 males were enrolled for the study. After a complete ophthalmic evaluation, the patients underwent trabeculectomy. Full ophthalmic examination was done the next day, which included visual acuity, intraocular pressure (IOP), and bleb morphology. Next, two drops of bevacizumab [0.25 mg (0.01 ml)] were instilled over the wound area with a tuberculin (1 ml) syringe. Pressure was applied at the medial canthus to prevent it from going into the lacrimal passage. Similar postoperative procedures were repeated at 1, 2, 3, and 4 weeks. So in all, five instillations of bevacizumab were completed. Later, the patients were followed at 1-month interval for 6 months. Target IOP was achieved in all eyes and was maintained during the study period of 6 months without any anti-glaucoma medication. Average IOP before trabeculectomy was 27.27±8.92 mmHg, which decreased postoperatively to 8.77±0.97 mmHg at 3 months and 9.27±1.16 mmHg at 6 months. This drop in IOP was statistically significant on both occasions (p=0.00). A nice low filtering bleb was formed after the surgery, and it remained the same during the study period. The other parameters like cup-to-disc ratio and visual field did not change during the 6 months of study as expected because glaucoma is a slow progressive disease. Modulating the wound at multiple sites by bevacizumab (inflammation, proliferative, and remodeling stages) can lead to success of trabeculectomy.

show abstract

Section: Discussionmentioning

confidence: 99%

Post-trabeculectomy topical bevacizumab preventing bleb failure: a preliminary study

Bhasker

Saxena

Singh

2012

j ocul biol dis inform

View full text Add to dashboard Cite

show abstract

“…Kim i suradnici aplicirali su 1,25 % topički bevacizumab 2 puta dnevno tijekom 3 mjeseca. Šest od 10 očiju razvilo je epiteliopatiju u drugom mjesecu liječenja, što upućuje na poremećaj adhezije između epitela i bazalne membrane rožnice ili poremećaja u procesu cijeljenja epitela rožnice 29 . Dong i suradnici aplicirali su subkonjunktivalne injekcije bevacizumaba u koncentracijama 1,2,5 i 25 mg/ml, te zapazili da degeneraciju živaca rožnice, smanjenu rožničnu osjetljivost i produljeno zacjeljivanje rožnice kod viših koncentracija bevacizumaba i nakon ponavljanih injekcija, a promjene su bile reverzibilne kod jedne subkonjunktivalne injekcije 1 -5 mg/ml bevacizumaba 30 .…”

Section: Nuspojaveunclassified

Bevacizumab and corneal pathology

Babić

Merlak

2017

Med. flum.

View full text Add to dashboard Cite

Sažetak. Cilj rada je dati pregled postojeće literature o terapiji bevacizumabom u liječenju neovaskularnih poremećaja rožnice. Rožnica je jedinstveno tkivo zbog svoje prirodne avaskularnosti. Imunoprivilegirano je vezivno tkivo koje služi kao mehanička prepreka i prednja refraktivna površina oka. Krvnu opskrbu prima perilimbalnim cilijarnim arterijama. Neovaskularizacija (NV) rožnice je stanje koje obilježava patološko urastanje perilimbalnih krvnih žila u rožnicu, zbog kroničnog nedostatka kisika. Patološka stanja koja uzrokuju neoangiogenezu rožnice su kemijske ozljede, ishemija, infekcije, degeneracije, trauma i imunološki procesi. Abnormalne krvne žile uzrokuju stvaranje ožiljaka rožnice i kompromitiraju vidnu oštrinu. Neovaskularizacija rožnice nastaje kada je ravnoteža između pro-angiogenih i anti-angiogenih faktora narušena u korist pro-angiogenih molekula. Dosadašnji uobičajeni tretmani za liječenje NV-a rožnice imaju ograničenu kliničku djelotvornost jer ne ciljaju molekularne posrednike angiogeneze. VEGF-A (engl. Vascular Endothelial Growth Factor-A) je glavni regulator hemangiogeneze. Bevacizumab prepoznaje sve VEGF izoforme. Neovaskularna stanja rožnice koja se mogu liječiti bevacizumabom su: inflamatorna stanja, infekcije i traumatski/jatrogeni uzroci. Studije su pokazale djelomično smanjenje neovaskularizacija rožnice kroz topičku, subkonjunktivalnu i intrastromalnu primjenu bevacizumaba. Anti-VEGF terapija stvorila je ogromnu nadu za liječenje neovaskularizacije rožnice, no ona ima svoje granice u liječenju, a uspješnost liječenja ovisi o veličini ožiljka, trajanju bolesti i opsegu neovaskularizacija. Anti-VEGF terapija je posebno učinkovita ako se primijeni u ranoj fazi (prva 2 tjedna neoangiogeneze). Kontrolirane prospektivne studije potrebne su za uspostavu dugoročne sigurnosti i određivanje minimalne efektivne i maksimalne sigurnosne koncentracija bevacizumaba za liječenje NV-a prednjeg segmenta oka.Ključne riječi: bevacizumab; patologija rožnice; rožnica; vaskularni endotelni faktori rasta Abstract. The purpose of this paper is to present a review of the current literature on anti-vascular endothelial growth factor (anti-VEGF) bevacizumab therapy for corneal neovascular disorders. Cornea is unique avascular, immunoprivileged connective tissue that acts as transparent mechanical barrier and the anterior eye refractive surface. Corneal neovascularizations (NV) are caused by chronic corneal ischemia with pathological ingrowth of perylimbal blood vessels into the cornea. Abnormal blood vessels cause scarring of the cornea and compromise visual acuity. Pathological conditions that cause corneal neoangiogenesis are: chemical burns, ischemia, infections, degeneration, trauma and immune processes. Corneal neovascularization occurs because of corneal pro-angiogenic and anti-angiogenic factors disequilibrium. The former treatment of corneal NV does not target the molecular mediators of angiogenesis. VEGF-A is the main regulator of angiogenesis. Bevacizumab recognizes all VEGF isoforms. Studies have de...

show abstract

“…Although most reports conclude that topical anti-VEGF therapy for corneal neovascularisation appears safe, adverse effects such as corneal thinning and reduced epithelial healing have also been acknowledged. 83 These may be due to neurotrophic effects of VEGF, leading to reduction of the numerous corneal nerves when VEGF is inhibited. 84 Currently, no data from randomised controlled clinical trials is available.…”

Section: Translational Aspects Of Corneal Angiogenesis and Clinical Ementioning

confidence: 99%

Emerging techniques to treat corneal neovascularisation

Menzel‐Severing

2011

Eye

View full text Add to dashboard Cite

Neovascularisation is a major cause of visual loss in a number of ophthalmic diseases. This review aims to outline the basic regulators of vessel growth in corneal neovascularisation. An understanding of the underlying principles of physiological and pathophysiological vascular development helps to appreciate current approaches to prevent or treat corneal neovascularisation. Options for future interventions will be discussed in the light of recent evidence provided by animal models of corneal neovascularisation.

show abstract

The Effect of Topical Bevacizumab on Corneal Neovascularization

Cited by 203 publications

References 24 publications

Post-trabeculectomy topical bevacizumab preventing bleb failure: a preliminary study

Post-trabeculectomy topical bevacizumab preventing bleb failure: a preliminary study

Bevacizumab and corneal pathology

Emerging techniques to treat corneal neovascularisation

Contact Info

Product

Resources

About